Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of AVROBIO, Inc. (NASDAQ: AVRO) resulting from allegations that AVROBIO may have issued materially misleading business information to the investing public.
If you purchased AVROBIO securities and would like to join the prospective action, please click “Join This Class Action.”
On May 3, 2021, before market hours, AVROBIO issued a press release entitled “AVROBIO Provides Regulatory Update on Investigational AVR-RD-01 for Fabry Disease” which announced that “AVROBIO can no longer pursue an accelerated approval pathway for AVR-RD-01 with the FAB-GT trial as currently designed[.]”
On this news, AVROBIO share prices fell $2.20 per share, or 18%, to close at $9.48 on May 3, 2021.
自 2013 年以来，罗森律师事务所每年都是代表投资者成功提起证券集体诉讼的前四大律所之一。仅 2019 年，本律所就为投资者追回 4.38 亿美元资金。
投资者应仔细鉴别和遴选在引领证券集体诉讼方面有多年成功经验的的律师。通常，其他律所会发布关于集体诉讼的新闻稿，但却没有类似的经验或资源。
机构股东服务公司按 2017 年证券集体诉讼索赔数量，罗森律师事务所列为第一名。
罗森律师事务所为全球投资者提供代理服务。我们的使命是提起证券欺诈集体诉讼以及保护股东的权利。
